The Efficacy of Drug-eluting Bead Transarterial Chemoembolization Loaded With Oxaliplatin for the Treatment of Stage III-IV Non-small-cell Lung Cancer

Published:February 14, 2022DOI:

      Rationale and Objectives

      To explore the safety and efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) loaded with oxaliplatin for stage III-IV non-small-cell lung cancer (NSCLC).

      Materials and Methods

      From October 2018 to May 2021, a total of 31 patients with stage III-IV NSCLC received DEB-TACE loaded with oxaliplatin. Demographic characteristics, adverse events (AEs), and treatment responses were collected. Overall survival (OS) and progression-free survival (PFS) were calculated using the Kaplan–Meier method.


      All 31 patients successfully received DEB-TACE loaded with oxaliplatin. No procedure-related severe adverse events occurred. Hemoptysis symptoms presented in 8 patients but disappeared within 1-3 days. After DEB-TACE for 1, 2, and 6 months, the objective response rate (ORR) was 42%, 35%, and 26%, while the disease control rate (DCR) was 90%, 84% and 61%, respectively. The median PFS was 7 months (range 1-31 months), and the PFS rates at 3, 6, and 12 months were 87%, 71% and 29%, respectively. The median OS was 11 months (range 1-31 months), with OS rates of 87%, 77%, and 39% at 3, 6, and 12 months, respectively.


      Oxaliplatin-loaded DEB-TACE is a feasible, safe, and effective treatment for patients with advanced refractory non-small-cell lung cancer.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Academic Radiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Duma N.
        • Santana-Davila R.
        • Molina J.R.
        Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment.
        Mayo Clin Proc. 2019; 94: 1623-1640
        • Bie Z.
        • Li Y
        • Li B
        • et al.
        The efficacy of drug-eluting beads bronchial arterial chemoembolization loaded with gemcitabine for treatment of non-small cell lung cancer.
        Thorac Cancer. 2019; 10: 1770-1778
        • Lin H.
        • Wang Q
        • Tian F
        • et al.
        Drug-eluting beads bronchial arterial chemoembolization in treating relapsed/refractory small cell lung cancer patients: results from a pilot study.
        Cancer Manag Res. 2021; 13: 6239-6248
        • Ettinger DS
        • Wood DE
        • Aggarwal C
        • et al.
        NCCN guidelines insights: non–small cell lung cancer, version 1.2020.
        J Natl Compr Canc Netw. 2019; 17: 1464-1472
        • Bittoni MA
        • Arunachalam A
        • Li H
        • et al.
        Real-world treatment patterns, overall survival, and occurrence and costs of adverse events associated with first-line therapies for medicare patients 65 years and older with advanced non–small-cell lung cancer: a retrospective study.
        Clinical Lung Cancer. 2018; 19: e629-e645
        • Raoul JL
        • Forner A
        • Bolondi L
        • et al.
        Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence.
        Cancer Treat Rev. 2019; 72: 28-36
        • Melchiorre F
        • Patella F
        • Pescatori L
        • et al.
        DEB-TACE: a standard review.
        Future Oncol. 2018; 14: 2969-2984
        • Kwan K.C.
        Oral bioavailability and first-pass effects.
        Drug Metab Dispos. 1997; 25: 1329-1336
        • Bi Y
        • Shi X
        • Ren J
        • et al.
        Clinical outcomes of doxorubicin-eluting CalliSpheres® beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma.
        BMC Gastroenterology. 2021; 21: 231
        • Bi Y
        • Wang Y
        • Zhang J
        • et al.
        Clinical outcomes of uterine arterial chemoembolization with drug-eluting beads for advanced-stage or recurrent cervical cancer.
        Abdom Radiol(NY). 2021; 46(12): 5715-5722
        • Sederholm C
        • Hillerdal G
        • Lamberg K
        • et al.
        Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish lung cancer study group.
        J Clin Oncol. 2005; 23: 8380-8388
        • Du L
        • Morgensztern D.
        Chemotherapy for advanced-stage non-small cell lung cancer.
        Cancer J. 2015; 21: 366-370
        • Atmaca A
        • Al-Batran SE
        • Werner D
        • et al.
        A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer.
        Br J Cancer. 2013; 108: 265-270
        • Mir O
        • Boudou-Rouquette P
        • Giroux J
        • et al.
        Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer.
        Lung Cancer. 2012; 77: 104-109
        • Kim HS
        • Kim JH
        • Yang I.
        Tumor response assessment by measuring the single largest lesion per organ in patients with advanced non-small cell lung cancer.
        Lung Cancer. 2014; 85: 385-389
        • Yu G.
        • Hu J.
        Drug-eluting beads bronchial arterial chemoembolization as a neoadjuvant treatment for squamous non-small cell lung cancer.
        Postgrad Med. 2020; 132: 568-571
        • Liu X
        • Lin H
        • Wang Q
        • et al.
        Drug-eluting beads bronchial arterial chemoembolization plus intercostals arterial infusion chemotherapy is effective and well- tolerated in treating non-small cell lung cancer patients with refractory malignant pleural effusion.
        J Thorac Dis. 2021; 13: 2339-2350
        • Gershman E
        • Guthrie R
        • Swiatek K
        • et al.
        Management of hemoptysis in patients with lung cancer.
        Ann Transl Med. 2019; 7: 358
        • Savic L.J.
        • Chapiro J.
        • Geschwind J.H.
        Intra-arterial embolotherapy for intrahepatic cholangiocarcinoma: update and future prospects.
        Hepatobiliary Surg Nutr. 2017; 6: 7-21
        • Han K
        • Yoon KW
        • Kim JH
        • et al.
        Bronchial artery embolization for hemoptysis in primary lung cancer: a retrospective review of 84 patients.
        J Vasc Interv Radiol. 2019; 30: 428-434
        • Fujita T
        • Tanabe M
        • Moritani K
        • et al.
        Immediate and late outcomes of bronchial and systemic artery embolization for palliative treatment of patients with nonsmall-cell lung cancer having hemoptysis.
        Am J Hosp Palliat Care. 2014; 31: 602
        • Maschke SK
        • Werncke T
        • Klöckner R
        • et al.
        Quantification of perfusion reduction by using 2D-perfusion angiography following transarterial chemoembolization with drug-eluting beads.
        Abdom Radiol (NY). 2018; 43: 1245-1253
        • Shahin Y.
        • Rothman A.M.
        Commentary on: evaluation of a newly developed 2D parametric parenchymal blood flow technique with an automated vessel suppression algorithm in patients with chronic thromboembolic pulmonary hypertension undergoing balloon pulmonary angioplasty.
        Clin Radiol. 2019; 74: 435-436